Abstract
For decades, docetaxel has been the standard salvage chemotherapy for patients with advanced non-small cell lung cancer (aNSCLC) after progression on platinum-doublet chemotherapy. Standard first-line therapy has evolved to incorporate early use of immunotherapy with PD-(L)1 inhibitors. The impact of immunotherapy on the efficacy of subsequent chemotherapy remains unclear. This real-world study aimed to assess overall survival (OS) of patients with aNSCLC treated with taxane-containing regimen after immunotherapy and platinum-doublet chemotherapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
